Expert Interview
Digging in to the results from the Phase 3 study of Valneva's single-shot chikungunya vaccine candidate, VLA1553.
Ticker(s): VALNInstitution: University of California Los Angeles
- Assistant Professor of Microbiology, Immunology & Molecular Genetics at UCLA
- Main focus of the Li Lab is to elucidate the mechanisms of antiviral IFNs and ISGs using molecular biology, biochemistry, genome-wide approaches, and stem cell culture systems
- Publications on Zika Virus, antiviral processes, viral RNA, Zinc Finger Antiviral Protein (ZAP), and Interferon-Stimulated Genes.
What are your key take aways from the Phase 3 study of VLA1553?
Added By: sara_adminOn a scale from 1-10 (10 being extremely excited, where would you rate your level of excitement for VLA1553?
Added By: sara_adminFor this call, I hope to get your opinion on the potential of a Chikungunya vaccine from Valneva. Are you familiar with the other phase three from Bavarian Nordic and their different technology for their vaccine for Chikungunya?
Can you provide a little bit of background information about yourself and your area of expertise? Also, a few details about your current practice setting?
Can you provide some background on the need for a vaccine for Chikungunya? Discuss the disease burden that a typical patient will have and the overall need for a vaccine.
Are there any up-to-date prevalence numbers for Chikungunya in the southern United States? Should someone in Michigan or the Northeast consider getting a vaccine?
Regarding the Valneva clinical trial, what inferences can you draw about its patient benefits based on their focus on antibody levels?
How do you weigh the efficacy of a vaccine versus its tolerability and side effect profile?
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
